Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s509176 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ruanjuan Zhan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Purines, Tandem Mass Spectrometry, Drug Monitoring, Azetidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Baricitinib is widely used as a selective Janus kinase (JAK) inhibitor for the treatment of immune-mediated inflammatory diseases in clinic. It is now successfully applied in reducing inflammation and suppressing COVID-19-associated immune dysregulation. As knowledge of the appropriate plasma level of baricitinib in COVID-19 patients is deficient, the measurement of the level of baricitinib in plasma during treatment is necessary and important.
Purpose
The aim of this study was to establish a bioanalytical method to detect the concentration of baricitinib in COVID-19 patients' plasma by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
Methods
The preparation process of the injected sample was to spike 100 μL of plasma and 10 μL of internal standard (IS, upadacitinib) working solution, then add 1:3 of acetonitrile to obtain the supernatant. The intra-day and inter-day precision and accuracy, matrix effect, recovery, and stability of the established methodology were all required.
Results
The method was established to determine the plasma levels in 22 COVID-19 patients. After taking 2 mg/day or 4 mg/day of baricitinib, the mean plasma concentrations of the patients were 15.36 ng/mL and 12.64 ng/mL, respectively.
Conclusion
This novel UPLC-MS/MS method enables rapid and accurate determination of baricitinib concentrations in human plasma, which is suitable for the therapeutic drug monitoring (TDM) of baricitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Ruanjuan Zhan, Xiaohai Chen
Zitieren
APA
Zhan, R., Shen, Y., Fu, H., Wu, H., Chen, X., Yu, Y., & Xu, R. A. (2025). Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s509176
Vancouver
Zhan R, Shen Y, Fu H, Wu H, Chen X, Yu Y, et al. Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s509176
BibTeX
@article{Zhan2025,
author = {Zhan, Ruanjuan and Shen, Yuxin and Fu, Haoxin and Wu, Hualu and Chen, Xiaohai and Yu, Yige and Xu, Ren-Ai},
title = {Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s509176}
}
EUVIMED